Wave Life Sciences (WVE)
Prix: 5.87Entreprise et modèle économique
Wave Life Sciences is a biotechnology company focused on developing therapies for genetic diseases. Its core products include RNA-targeted medicines, with a primary emphasis on treating conditions such as Duchenne muscular dystrophy and other rare diseases. The company operates in the healthcare sector, generating revenue primarily through research and development collaborations and potential future product sales.
Profil d’investissement
The investment profile of Wave Life Sciences is more aligned with growth investors due to its focus on innovative therapies and potential for significant revenue increases. However, the high risk associated with its current financial performance and market volatility suggests caution. The stock may appeal to those with a medium to long-term investment horizon who are comfortable with higher risk levels.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -1.06 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- 121.8% ↑
- Surprise BPA
- 61.8% meilleur que prévu
- Volatilité 20 j
- 3.5% stable
Impact de la prévision
positifSuivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-05-28 03:37 | Conserver | Vendre | scenario_deterioration |
| 2026-05-24 02:55 | Vendre | Conserver | Weak fundamentals and negative momentum raise significant risk. |
| 2026-05-08 15:20 | — | Vendre | Weak momentum and high risk offset potential gains. |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-11 10:43 | New Street | Mettre à jour | — → 13 | 5.66 |
| 2026-05-20 10:29 | Wells Fargo | Objectif relevé | 13 → 14 | 6.14 |
| 2026-05-19 10:44 | H.C. Wainwright | Objectif abaissé | 18 → 13 | 6.4 |
Rien pour le moment